Agreement includes exclusive distribution of PurePep Coupling Agents in North America
Uppsala, Sweden, 25 April 2017: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, announced today it has signed an exclusive distribution agreement with Luxembourg Bio Technologies for two of its proprietary coupling agents, PyOxim® and K-Oxyma®, and HDMA on a non-exclusive basis. Gyros Protein Technologies will sell these reagents as part of its PurePep™ brand.
Under the terms of the agreement, Gyros Protein Technologies has the exclusive rights to promote and sell these PurePep products to researchers in North America, and globally on a non-exclusive basis. The addition of the PurePep Coupling Agents to Gyros Protein Technologies’ offering further enables researchers to efficiently synthesize simple to complex peptides, by increasing coupling efficiency and reducing racemization. All chemicals are 100% QC tested to deliver consistently high peptide purity and yield. The suite of PurePep Coupling reagents is available in standard and custom pack sizes.
Jasmine Gruia-Gray, VP Marketing, Gyros Protein Technologies, commented: “Gyros Protein Technologies takes pride in providing high quality peptide synthesis reagents and platforms. At the core of Gyros Protein Technologies’ PurePep product brand is purity, trust and ingenuity in peptide synthesis, supporting the Company’s pure reliability solution strategy – synthesizers, software and reagents, which are in turn underpinned by our decades-long track record of providing customers with outstanding service and support. We are pleased to partner with Luxembourg Bio Technologies, given their strong market position as a provider of high quality and innovative peptide synthesis reagents.”
Gyros Protein Technologies’ peptide synthesizer platforms are used in conjunction with PurePep reagents, which include bulk and pre-packed amino acids, resins, coupling agents and solvents. Peptide synthesis optimization using these reagents minimizes down time caused by clogging that can result from using impure and unstable reagents. The platforms ensure that peptides are synthesized correctly the first time, with consistent quality and reduced synthesis variability.
Yoav Luxembourg, CEO of Luxembourg Bio Technologies, said: “We are pleased to have Gyros Protein Technologies as our partner, and our distribution agreement represents an important step to enable more researchers to have access to the highest quality coupling agents designed to provide maximum yield with minimal racemization.”
Established in March 2016 by the merger of Gyros AB and Protein Technologies, Inc., Gyros Protein Technologies combines Gyros’ microfluidics, systems development and immunoassay expertise with Protein Technologies’ deep knowledge in developing and manufacturing instruments for peptide synthesis. The Company provides customers an unrivaled range of peptide synthesis and bioanalytical tools for bio therapeutics discovery, development and bioprocessing.
Notes to editors
Media contact:
Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: Katie.odgaard@zymecommunications.com
About Gyros Protein Technologies
Gyros Protein Technologies enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Our low to mid-scale peptide synthesizer platforms are the Tribute®, Prelude® X, Symphony® X, and Sonata®. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab™ xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics.
About Luxemburg Bio Technologies (For more information please click here)
At Luxembourg Bio Technologies, we specialize in providing products to address your peptide, amides and bond reagents synthesis needs. Many of our coupling reagents, especially our proprietary products, are designed to provide maximum yield with minimal racemization. We are here to help you, whether you are using Boc, CBZ , PNZ or Fmoc chemistry, and solid-phase or solution-phase peptide synthesis.
Luxembourg Bio Technologies believes in using green chemistry and sustainable methods whenever possible, and many of our products are designed to be compatible with environmental friendly conditions. We work under the most rigorous quality assurance standards available to provide you with the best possible quality products, such as COMU, HDMC, OxymaPure, PyOxim, PyBOB, DEPBT, and many others. Our products are being applied in a wide range of areas, including peptide and oligonucleotide synthesis.
Luxembourg Bio Technologies patented IP materials will provide you with every advantage when facing the needs of an ever-growing pharmaceutical industry, and our sustainable production methods ensure safer products with a smaller ecological footprint.